Literature DB >> 3665986

Antitumor activity of antiestrogenic phenylindoles on experimental prostate tumors.

M R Schneider1, E von Angerer, W Höhn, F Sinowatz.   

Abstract

Two antiestrogenic phenylindoles (D 16726 and D 15413) were tested for their prostatic tumor-inhibiting activity. Both compounds exerted a strong inhibitory effect on prostate and seminal vesicle weight of intact rats and mice comparable to that of diethylstilbestrol. Their estrogenic properties, however, are much lower than those of DES. Therefore, there is no direct correlation between estrogenic potency and inhibition of accessory sex organ weights. The tumor-inhibiting activity of D 16726 and D 15413 on the androgen-dependent R 3327 Dunning prostatic carcinoma and the human prostatic tumor PC 82 implanted in nude mice equals that of castration or of diethylstilbestrol. Both 2-phenylindoles had good affinities for estrogen receptors from calf uterine and R 3327 tumor cytosol, but no affinities for androgen and progesterone receptors. As these 2-phenylindoles have much lower estrogenic properties than diethylstilbestrol, they may also have low side-effects, and can therefore be of interest for the therapy of the prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665986     DOI: 10.1016/0277-5379(87)90350-6

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  11 in total

1.  The effect of a combination of zindoxifene and cisplatin on Dunning R3327-G prostatic carcinomas of the rat.

Authors:  E von Angerer; H Birnböck; M Kager; A Maucher
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation.

Authors:  M Kager; T Spruss; M R Schneider; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Ester derivatives of the mammary-tumor-inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane.

Authors:  W Schwarz; R W Hartmann; J Engel; M R Schneider; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.

Authors:  Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Thilo Spruss; Anton Maucher; Erwin von Angerer; Claus D Schiller; Martin R Schneider; Ronald Gust; Helmut Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-06       Impact factor: 4.553

5.  Androgen-linked alkylating agents: biological activity in methylnitrosourea-induced rat mammary carcinoma.

Authors:  H P Brix; M R Berger; M R Schneider; W C Tang; G Eisenbrand
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

6.  Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.

Authors:  A Maucher; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Evaluation of the antitumour activity of coumarin in prostate cancer models.

Authors:  A Maucher; M Kager; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  The tumor-inhibiting effect of diethylstilbestrol and its diphosphate on the Nb-H and Nb-R prostatic carcinomas of the rat.

Authors:  M R Schneider; A Humm; A H Graf
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

9.  Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma.

Authors:  C D Schiller; M R Schneider; H Hartmann; A H Graf; H Klocker; G Bartsch
Journal:  Urol Res       Date:  1991

10.  Effect of zindoxifene on experimental prostatic tumours of the rat.

Authors:  M R Schneider; C D Schiller; A Humm; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.